01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
17:53 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regulatory reforms in China spark Samsung Bioepis deal with 3SBio

The regulatory reforms and growing China biopharma market has led South Korean company Samsung Bioepis Co. Ltd. (Incheon, South Korea) to expand its commercial reach via a deal with 3SBio Inc. (HKSE:1530). Samsung Bioepis said...
17:46 , Jan 11, 2019 |  BC Week In Review  |  Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
20:42 , Jan 8, 2019 |  BC Extra  |  Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
00:59 , Jan 8, 2019 |  BC Extra  |  Company News

Regulatory reforms in China spark Samsung Bioepis deal with 3SBio

The regulatory reforms and growing China biopharma market has led South Korean company Samsung Bioepis Co. Ltd. (Incheon, South Korea) to expand its commercial reach via a deal with 3SBio Inc. (HKSE:1530). Samsung Bioepis said...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
13:43 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Endocrine/metabolic

INDICATION: Obesity Cell culture, mouse and non-human primate (NHP) studies suggest inhibiting the GIP receptor alone or in combination with GLP-1R agonists could help treat obesity. In a mouse model of diet-induced obesity, a mouse...
19:07 , Nov 9, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry; drug platforms

TECHNOLOGY: Synthetic chemistry; conjugates A method for linking methionine residues to small molecules could be used to generate novel therapeutic protein-drug conjugates. The method involves two steps: adding a diazo-iodonium salt to a protein or...
23:41 , Sep 12, 2018 |  BC Extra  |  Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
23:55 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Dental

INDICATION: Dental Patient sample and rat studies suggest promoting reactive oxygen species (ROS) production with Feraheme ferumoxytol and hydrogen peroxide could help treat dental caries (tooth decay). In Streptococcus mutans biofilms cultured on enamel-like hydroxyapatite,...